BridgeBio Pharma Net Income 2018-2026 | BBIO
BridgeBio Pharma annual/quarterly net income history and growth rate from 2018 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
- BridgeBio Pharma net income for the quarter ending June 30, 2026 was $-0.152B, a 16.32% decline year-over-year.
- BridgeBio Pharma net income for the twelve months ending June 30, 2026 was $-0.692B, a 10.89% decline year-over-year.
- BridgeBio Pharma annual net income for 2025 was $-0.725B, a 35.31% increase from 2024.
- BridgeBio Pharma annual net income for 2024 was $-0.536B, a 16.7% decline from 2023.
- BridgeBio Pharma annual net income for 2023 was $-0.643B, a 33.67% increase from 2022.
|
BridgeBio Pharma Annual Net Income (Millions of US $) |
|
|---|---|
| 2025 | $-725 |
| 2024 | $-536 |
| 2023 | $-643 |
| 2022 | $-481 |
| 2021 | $-563 |
| 2020 | $-449 |
| 2019 | $-261 |
| 2018 | $-131 |
| 2017 | $-31 |
|
BridgeBio Pharma Quarterly Net Income (Millions of US $) |
|
|---|---|
| 2026-06-30 | $-152 |
| 2026-03-31 | $-164 |
| 2025-12-31 | $-193 |
| 2025-09-30 | $-183 |
| 2025-06-30 | $-182 |
| 2025-03-31 | $-167 |
| 2024-12-31 | $-265 |
| 2024-09-30 | $-162 |
| 2024-06-30 | $-73 |
| 2024-03-31 | $-35 |
| 2023-12-31 | $-168 |
| 2023-09-30 | $-177 |
| 2023-06-30 | $-158 |
| 2023-03-31 | $-140 |
| 2022-12-31 | $-138 |
| 2022-09-30 | $-137 |
| 2022-06-30 | $-10 |
| 2022-03-31 | $-196 |
| 2021-12-31 | $-147 |
| 2021-09-30 | $-156 |
| 2021-06-30 | $-96 |
| 2021-03-31 | $-163 |
| 2020-12-31 | $-120 |
| 2020-09-30 | $-116 |
| 2020-06-30 | $-121 |
| 2020-03-31 | $-92 |
| 2019-12-31 | $-73 |
| 2019-09-30 | $-60 |
| 2019-06-30 | $-66 |
| 2019-03-31 | $-61 |
| 2018-09-30 | $-31 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |